An overview of several key areas of antitrust risk for brand-name and generic pharmaceutical companies, including a discussion of antitrust claims that may result from patent and regulatory activities, pricing and marketing decisions, and FTC and government enforcement efforts in areas such as reverse payment settlement agreements (pay-for-delay), product hopping, and abuse of government processes. This Practice Note also reviews the antitrust analysis of pharmaceutical mergers and acquisitions.